Cogentus Pharmaceuticals Completes $62.5 Million Private... (stablishing sites and recruiting patient...)

Cogentus Pharmaceuticals Completes $62.5 Million Private Financing

Date:12/20/2007

stablishing sites and recruiting patients for the first phase 3 clinical trial of its lead compound CGT-2168. A combination medicine pairing clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) in a single pill, CGT-2168 is designed to significantly reduce the gastrointestinal side effects commonly associated with dual antiplatelet therapy.

The phase 3 clinical trials, known as COGENT-1 and COGENT-2 (Clopidogrel and the Optimization of Gastrointestinal Events Trials), are expected to enroll approximately 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America.

Antiplatelet therapy is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events. However, treatment with antiplatelet medicines -- including aspirin, clopidogrel, or a combination of the two -- is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.

"We believe that antiplatelet medicines are crucial in the treatment of cardiovascular disease but that their risks have been under-appreciated," Dr. Goldsmith said. "CGT-2168 may prove to be the first agent to offer a significant safety advantage for the many cardiac patients who require dual antiplatelet treatment."

ABOUT COGENTUS

Cogentus Pharmaceuticals Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Cogentus was represented in the financing by O'Melveny & Myers LLP of Menlo Park, CA.

Plavix(R) is a registered trademark of Sanofi-Aventis.

SOURCE Cogentus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:

(Date:12/15/2009)... to Work For. , ... Alpharetta, GA (Vocus) Dec. ... provider of temporary physician and CRNA staffing, as the #4 Best ... , , ,“We are proud to be recognized on this list ... associates,” said R. Shane Jackson president of LocumTenens.com. “Unquestionably, we know ...

(Date:12/15/2009)... require that certain businesses with large areas where people gather, ... available. Fire and rescue personnel agree that for any size ... , ... Issaquah, WA (PRWEB) December ... that certain businesses with large areas where people gather, need ...

(Date:12/15/2009)... A study in the Dec. 15 issue ... indicates that significant associations exist between parent-reported ... and headaches in young school-aged children. , ... insomnia was 3.3 times more likely in children ... in children with headaches. Nineteen percent of ...

(Date:12/14/2009)... combination of AQUALIPO™ and NaturalFill™ revolutionary new liposuction and fat ... and plump lips all in one minimally invasive treatment. ... ... The combination of AQUALIPO™ and NaturalFill™ can remove excess fat ... lips to help people slim down, reduce facial wrinkling and ...

(Date:12/14/2009)... 14 Haemonetics Corporation (NYSE: ... a new legal action to stop Fenwal Inc.,s ... red cell collection kits, using a modified separation ... to circumvent Haemonetics, patent and the injunction entered ... infringing products after December 1, 2010. According ...

Breaking Medicine News(10 mins):Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2 Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2 Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3 Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2 Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3 Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2 Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3

[0] LocumTenens.com Named 4th Best Staffing Firm to Work For [0] QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators [1] Insomnia symptoms linked with medical complaints in young school-aged children [0] Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling [0] Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement

... Call on Friday, November 14th, FORT LAUDERDALE, Fla., ... leading provider of convenient at-home diet, fitness,and healthy lifestyle ... third quarter ended September 30, 2008, after the U.S.,equity ... company will also host a conference call for investors ...

... of Regence workers participate in annual giving effort, ... campaign record and bucked a national trend that threatens,charitable ... outlook -- or perhaps because of it --,Regence employees ... the company,s 50 percent match, local communities will,receive a ...

... for Medicare,& Medicaid Services (CMS) today announced that ... review 2009 Medicare,prescription drug plan and health plan ... and Medicare Options Compare at, http://www.medicare.gov ., ... throughout the upcoming,open enrollment period, for beneficiaries to ...

... Nov. 10 For Emmy-award winning actor Hector,Elizondo, the ... are very personal. In the 1960s, Elizondo,s mother was ... brain,causing impaired thinking, memory, and attention., For Elizondo,s ... a 24/7 commitment. Although the family was willing to ...

... Mich., Nov. 10 A study published today ... that annual,medical expenditures for Crohn,s disease patients are ... matched comparison group of patients. Similar,results were found ... examined both direct medical costs - inpatient and ...

... 10 Players for the NFL,s,Chicago Bears will visit ... North Chicago VA medical center, as part of the ... Jason McKie and running back Adrian Peterson are,scheduled to ... for serving,our nation by signing autographs, presenting patients with ...

Other Medicine News:Health News:eDiets.com(R) to Report Third Quarter 2008 Results on Thursday, November 13, 2008 2 Health News:Trend-Breaking Employee Campaign Raises Nearly $2.5 Million 2 Health News:Medicare's Online Tools Will Help Beneficiaries With Prescription Drug and Health Plan Choices for 2009 2 Health News:Medicare's Online Tools Will Help Beneficiaries With Prescription Drug and Health Plan Choices for 2009 3 Health News:Hector Elizondo: Caring for a Loved One with Alzheimer's Dementia 2 Health News:Hector Elizondo: Caring for a Loved One with Alzheimer's Dementia 3 Health News:Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From Thomson Reuters 2

eDiets.com(R) to Report Third Quarter 2008 Results on Thursday, November 13, 2008 Trend-Breaking Employee Campaign Raises Nearly $2.5 Million Medicare's Online Tools Will Help Beneficiaries With Prescription Drug and Health Plan Choices for 2009 Hector Elizondo: Caring for a Loved One with Alzheimer's Dementia Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From Thomson Reuters Chicago Bears Players Visit Hospitalized Veterans

(Date:12/14/2009)... Embarrassing and sometimes uncomfortable colonoscopies may soon ... are taking note of a new screening test that ... The Knoxville-based company, EDP Biotech Corporation (EDP) ... affordable medical device doctors can use to screen for ... you consider that 30% of colon cancer deaths are ...

(Date:12/14/2009)... Dec. 14 Seven leading ... US Oncology Research participated ... at the 2009 San Antonio ... 9-13 at the Henry B. ... Antonio, Texas . Fifteen others ...

(Date:12/14/2009)... 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Drug Application (NDA) for Staccato® loxapine (AZ-004) to the ... an inhalation product candidate being developed for the rapid ... disorder. The IND for Staccato loxapine ... "AZ-004 has delivered a predictable and consistent safety and ...

[0] EDP Biotech Takes Next Step in the Development of ColoMarker [0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium [0] Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA

... 24 Anthera Pharmaceuticals,announced today they have ... Drug,Administration (FDA) on a Phase 3 protocol ... under the FDA,s Special Protocol Assessment,procedure. At ... Advice from,the European Medicines Agency (EMEA) on ...

... has Completed Recruitment of Patients in the Phase III ... in Rituximab Refractory Follicular NHL, COPENHAGEN, September 23 ... recruitment of patients in the,pivotal Phase III study of ... patients,receiving treatment at the 1000 mg dose level of ...

Other Medicine Technology:Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 2 Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 3 Recruitment Completed in Ofatumumab NHL Pivotal Study 2 Recruitment Completed in Ofatumumab NHL Pivotal Study 3

Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval Recruitment Completed in Ofatumumab NHL Pivotal Study

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Insulin-Like Growth Factor Binding Protein-3 Insulin, 60 Minutes INR Inhibitor Assay, PTTwith Reflex to PTT 1:1 Mix 2-Hour Incubation

Cogentus Pharmaceuticals Completes $62.5 Million Private...(stablishing sites and recruiting patient...),Health